News | May 27, 2021
Strides Pharma Science posts consolidated PAT of Rs. 46.08 Cr in Q4FY21
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
This marks Glenmark's first synthetic decapeptide injectable approval
It posted net profit of Rs.188.77 crores for the period ended March 31, 2020.
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
First batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control and full scale production of the vaccine is due to start this summer
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
The company reported total income of Rs.455.28 crores during the 12 months period ended March 31, 2021
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
